S0888 Alternative Subcutaneous Biologic Dosing in Inflammatory Bowel Disease Is Delayed Depending on Insurance Approval Requirements

Authors :: Joshua DeClercq
David A. Schwartz
Elizabeth A. Scoville
Nisha Shah
Christopher L. Coe
Dawn B. Beaulieu
Robin Dalal
Sara N. Horst
Baldeep S. Pabla
Autumn D Zuckerman
Charles A. Donoho
Laura Cherry
Leena Choi
Source :: American Journal of Gastroenterology. 115:S458-S458
Publication Year :: 2020
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2020.

Subjects :: medicine.medical_specialty
Hepatology
business.industry
Internal medicine
Gastroenterology
medicine
Dosing
business
medicine.disease
Inflammatory bowel disease

Full Text Access

Tools